Roger B. Cohen, MD
Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West
Penn Medicine Provider

About me

  • Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: Harvard Medical School
  • Residency: Mount Sinai Medical Center
  • Fellowship: Mount Sinai Medical Center
  • Fellowship: National Cancer Institute

What my patients think about me

Average Rating

710 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
April 2026
doctor cohen sincerely cares about the wellbeing of his patients.
Anonymous
April 2026
exceptional care. all of our questions were. answered and we left more confident about the path forward.
Anonymous
April 2026
very efficient
Anonymous
April 2026
a long relationship between dr. cohen and i is very positive point.

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Cohen is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Qu K, Stalker M, Hwang WT, Cohen RB, Sun L. Recurrent/metastatic relapse after definitive treatment for HNSCC: timing, patterns, and survival , Front Oncol, 16: 2026,1738860


Barsouk A, Heidlauf A, Goel K, Rushkin L, Anran Huang A, Elghawy O, Yu C, Wang L, Yang D, Kurian M, Reed-Guy L, Sun L, Singh A, Aggarwal C, Cohen RB, Langer C, Marmarelis ME. Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) , Lung Cancer, 213: 2026,108936


Friedes C, Iocolano M, Yegya-Raman N, Kucharczuk JC, Pechet TTV, Cohen RB, Aggarwal C, Marmarelis ME, Levin WP, Cengel KA, Ciunci CA, D'Avella C, Singh AP, Davis CW, Langer CJ, Bradley J, Feigenberg SJ. Real World Radiographic Response Rates and Preoperative Attrition in Patients With Non-Small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy , Am J Clin Oncol: 2025


Yegya-Raman N, Ko K, Han IS, Mitchell JD, Zou W, Ohri N, Jabbour SK, Mak RH, Robinson C, Levin WP, Barrett L, Xia C, Berlin E, Bravo P, Carli MD, Cohen R, Hutton S, Keltz J, Wang J, Fasan O, Nagda SN, Seo A, Smith AM, Sun L, Soike M, Kole AJ, Walls G, Feigenberg SJ, Ky B. Cardiac substructure radiotherapy dose and changes in physical activity and quality of life after chemoradiotherapy for NSCLC: a secondary analysis of the CLARITY prospective study , Clin Transl Radiat Oncol, 56: 2025,101070


Gobillot TA, Weinstein G, Cao A, Lee JJ, Brody RM, Basu D, O'Malley BW Jr, Farwell DG, Cannady S, Lin A, Lukens J, Gentile M, Newman JG, Chalian AA, Sun L, Lakshmipathy D, Cohen RB, Rasskeh CH, Rajasekaran K. Outcomes of HPV+ Oropharyngeal Carcinoma of Unknown Primary Following Transoral Robotic Surgery , Laryngoscope: 2025


Theodore A Gobillot, Gregory Weinstein, Austin Cao, Jake J Lee, Robert M Brody, Devraj Basu, Bert W O'Malley Jr, D Gregory Farwell, Steven Cannady, Alexander Lin, John Lukens, Michelle Gentile, Jason G Newman, Ara A Chalian, Lova Sun, Deepak Lakshmipathy, Roger B Cohen, Christopher H Rasskeh, Karthik Rajasekaran Outcomes of HPV+ Oropharyngeal Carcinoma of Unknown Primary Following Transoral Robotic Surgery , The Laryngoscope: 2025


Cohen RB, Jimeno A, Hreno J, Sun L, Wallén-Öhman M, Millrud CR, Sanfridson A, Garcia-Ribas I. Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors , Invest New Drugs: 2025


Elghawy O, Barsouk A, Sussman JH, Bleiberg BA, Reed-Guy L, D'Avella C, Singh A, Ciunci C, Robinson K, Kosteva J, Langer C, Cohen RB, Aggarwal C, Marmarelis M, Sun L. Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC , JTO Clin Res Rep, 6: 2025,100851


Fayette J, Licitra L, Harrington K, Haddad R, Siu LL, Liu YC, Tahara M, Machiels JP, Rischin D, Seiwert TY, Ferris RL, Keilholz U, Psyrri A, Keam B, Bossi P, Metcalf R, Hsieh CY, Clement PMJ, Isaev P, Mudunov A, Dinis J, Hoeben A, Kasper S, Klinghammer K, Hwang M, Blando J, Serrano O, Ruscica D, Cohen RB. INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab Plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma , Clin Cancer Res, 31: 2025,2617-2627


Sannigrahi MK, Raghav L, Rich DJ, Schrank TP, Califano JA, Lukens JN, Sun L, Morgan IM, Cohen RB, Lin A, Liu X, Brown EJ, You J, Mirabello L, Mishra SK, Shimunov D, Brody RM, Pearson AT, Gimotty PA, Diab A, Jalaly JB, Basu D. Tumor-intrinsic and immune-related features associated with treatment failure in human papillomavirus-related oropharyngeal cancer , J Natl Cancer Inst, 117: 2025,1366-1376